Side Effects of Truvada, Atripla, Viread, Complera and Stribild
The lawyers at Saiontz & Kirk previously reviewed HIV drug lawsuits against Gilead for allegedly failing to warn about the toxic effect of medications that contained tenofovir disoproxil fumarate (TDF), and withholding the development of safer HIV treatments for years to maximize profits.
Our firm investigated Truvada, Atripla, Viread, Complera or Stribild HIV Drug Lawsuits for:
KIDNEY DAMAGE:
- Chronic Kidney Disease (CKD)
- Acute Kidney Injury
- Kidney Failure
- Dialysis Treatment
- Wrongful Death
BONE DENSITY LOSS:
- Bone Fractures
- Osteoporosis
- Osteopenia
- Osteaomalacia
- Tooth Loss or Dental Problems from Bone Deterioration
All HIV drug lawsuits were reviewed on a contingency fee basis, which means there were no fees or expenses unless a settlement or recovery was obtained.
History of TDF Drug Problems
Plaintiffs alleged that Gilead developed an essential monopoly over certain HIV “cocktail” drugs through a series of medications involving the antiretroviral tenofovir.
In 2001, Viread was introduced as the first HIV treatment featuring tenofovir disoproxil fumarate (TDF), which allowed the compound to be taken through a pill, avoiding the need for injections.
This was followed by the introduction of Truvada in 2004, Atripla in 2006, Complera in 2011 and Stribild in 2012, each involving different combination treatments with TDF. As a result, the drug maker was able to maintain blockbuster sales for their newest medications, and delay competition from generic HIV drugs.
Plaintiffs alleged that Gilead generated more than $11 billion in annual sales by marketing HIV and PrEP drugs with known toxic side effects on the kidneys and bones.
According to allegations previously raised in Gilead HIV drug lawsuits, the drug maker placed its desire for profits before consumer safety by delaying development of a known safer alternative design, known as tenofovir alafenamide (TAF), which is effective at a much lower and less toxic dose.
Gilead did not begin to introduce safer TAF drugs, such as Genvoya, Odefsey and Descovy, until the end of patent protection for TDF drugs approached in 2018.
Allegations Raised In Lawsuits
Saiontz & Kirk previously pursued claims for damages involving kidney and bone injuries allegedly caused by the toxic side effects of TDF drugs. According to allegations raised in the HIV treatment lawsuits, Gilead:
- Failed to warn about the risk of TDF toxicity
- Failed to recommend important monitoring for kidney function and bone mineral density
- Withheld a safer alternative HIV drug design for more than a decade
- Provided false and misleading information about the risks of TDF drugs
- Generated billions in sales by placing profits before the health of consumers
Real results. Real reviews.
Here’s what our clients have to say.
